Viropro, Inc. (VPRO)

[Penny Stocks 2.0]

Viropro International, Inc. (VPI), a 100% subsidiary of Viropro, Inc., will house Viropro, Inc.’s biosimilar technologies and associated technical developments for the purpose of commercialization through external partnerships. The starting line-up and portfolio consists of sophisticated biosimilar molecules such as Ranibizumab (biosimilar of Lucentis®), Trastuzumab (-Herceptin®), Rituximab (-Rituxan®), Bevacizumab (-Avastin®), Infliximab (-Remicade®) and Etanercept (-Enbrel®). It is from this portfolio that Viropro signed a Letter of Agreement with Spectrum Pharmaceuticals, Inc. for Rituximab, and is in active discussions with potential clients for its other biosimilar technologies. (“®” are registered trademarks of their respective owners.)